Comparative Pharmacology
Head-to-head clinical analysis: ATARAX versus CHILDREN S ALLEGRA HIVES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATARAX versus CHILDREN S ALLEGRA HIVES.
ATARAX vs CHILDREN'S ALLEGRA HIVES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine is a piperazine derivative with antihistaminic (H1-receptor antagonist) and anticholinergic properties; also exhibits sedative, anxiolytic, and antiemetic effects due to suppression of activity in subcortical areas of the CNS.
Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine-mediated effects, reducing pruritus and urticaria.
25 mg orally 3-4 times daily; maximum 100 mg per day. Also available as 50 mg intramuscular injection every 4-6 hours.
Fexofenadine 180 mg orally once daily for adults and children 12 years and older.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly, hepatic impairment, or renal insufficiency (up to 30-40 hours); steady-state achieved within 3-4 days.
Terminal half-life: 14.4 hours; clinical context: supports twice-daily dosing in chronic urticaria
Primarily hepatic metabolism via CYP3A4 and CYP2D6; renal excretion of metabolites accounts for approximately 70-80% of the dose, with less than 1% excreted unchanged; fecal excretion is about 10-15%.
Fecal (80% as unchanged drug); renal (15%, mostly as metabolites; <5% unchanged)
Category C
Category C
Antihistamine
Antihistamine